332 filings
Page 4 of 17
8-K
dwagewyo5ow90a ukup
23 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:13pm
424B5
jkztspo
22 May 23
Prospectus supplement for primary offering
4:02pm
NT 10-Q
5hgh9 rht
15 May 23
Notice of late quarterly filing
4:59pm
8-K
yes3dhyrsoub5
31 Mar 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:00pm
8-K
ci8ovm
16 Mar 23
T2 Biosystems Announces Fourth Quarter and Full Year 2022 Financial Results
4:01pm
8-K
lsi3e4mvma16i9piq
16 Feb 23
Other Events
4:17pm
424B5
04z42aneh3z8
16 Feb 23
Prospectus supplement for primary offering
4:14pm
424B5
xeoq znfk
13 Feb 23
Prospectus supplement for primary offering
4:09pm
8-K
v5j7b2iv3w
13 Feb 23
Other Events
4:05pm
8-K
j95 au7jzq
23 Jan 23
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results
5:11pm
8-K
0zdk8ymcxghe
25 Nov 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:01pm
8-K
d8m5g
10 Nov 22
T2 Biosystems Announces Third Quarter 2022 Financial Results
5:01pm
8-K
7c6ffb3g
7 Nov 22
Departure of Directors or Certain Officers
9:00am
8-K
ojdvk ndlqql80il
14 Oct 22
T2 Biosystems Highlights Multiple New Studies Demonstrating Improved Rapid Detection Across Several Patient Populations
9:00am
8-K
72teogr3y1qowgxn
13 Oct 22
T2 Biosystems Announces Plan to Commercialize a Diagnostic Test for Early Lyme Disease
9:00am
8-K
thg f0eyq4tas
12 Oct 22
Material Modifications to Rights of Security Holders
4:01pm
8-K
14iek5
12 Oct 22
T2 Biosystems Announces Preliminary Third Quarter 2022 Financial Results and Updates 2022 Financial Outlook
8:47am